Matches in Nanopublications for { ?s ?p "[PcG protein EZH2 is associated with adverse pathological features and clinical PSA recurrence of prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP103553.RAzyCNg0vIAYcKKYIYd5RXxKhG8sywaHo-0Ap0ZII7SqY130_assertion description "[PcG protein EZH2 is associated with adverse pathological features and clinical PSA recurrence of prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP103553.RAzyCNg0vIAYcKKYIYd5RXxKhG8sywaHo-0Ap0ZII7SqY130_provenance.
- assertion description "[PcG protein EZH2 is associated with adverse pathological features and clinical PSA recurrence of prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP120145.RA48K8GltWqoIFaLvFt1jWOlCwndNrDiWSq0-DHYRPH-A130_assertion description "[PcG protein EZH2 is associated with adverse pathological features and clinical PSA recurrence of prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP120145.RA48K8GltWqoIFaLvFt1jWOlCwndNrDiWSq0-DHYRPH-A130_provenance.
- NP166774.RAdWIsEClsW07TC-gS0e50mpj5C7G_WOZbBmpMp0cA8RY130_assertion description "[PcG protein EZH2 is associated with adverse pathological features and clinical PSA recurrence of prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP166774.RAdWIsEClsW07TC-gS0e50mpj5C7G_WOZbBmpMp0cA8RY130_provenance.
- NP183338.RAAboyTxcAwm3ziTIFzUukNbs8RaMv269Nb_AEzZqxAqI130_assertion description "[PcG protein EZH2 is associated with adverse pathological features and clinical PSA recurrence of prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP183338.RAAboyTxcAwm3ziTIFzUukNbs8RaMv269Nb_AEzZqxAqI130_provenance.
- NP221131.RAC56fx2xWRV5dXbr5SLKuy9KE6AluKh7hC18r3v9L0Ek130_assertion description "[PcG protein EZH2 is associated with adverse pathological features and clinical PSA recurrence of prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP221131.RAC56fx2xWRV5dXbr5SLKuy9KE6AluKh7hC18r3v9L0Ek130_provenance.